Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis.
We investigated the association between cerebral venous thrombosis and hereditary resistance to activated protein C (APC) in 12 consecutive German patients with non-fatal cerebral venous thrombosis and in 187 controls without a history of thrombotic disorder. Three patients (25%) had a mutation in the factor V Leiden gene against only one subject in the control group. This difference was significant (P < 0.05), with an odds ratio of 11.7 (1.5-87; 95% confidence interval). Two patients carrying the mutation had additional common risk factors for thrombosis, and 2 had a positive family history of thromboembolism. We conclude that inherited APC resistance by a mutation in factor V Leiden is an important risk factor in non-fatal cerebral venous thrombosis. We recommend testing for APC resistance and, if abnormal for factor V Leiden mutation in patients with cerebral venous thrombosis.
Weih
M
M
Department of Neurology, Charité and Virchow Hospital, Humboldt-University, Berlin, Germany. mweih@neuro.charite.hu-berlin.de
Vetter
B
B
Ziemer
S
S
Mehraein
S
S
Valdueza
J M
JM
Koscielny
J
J
Kulozik
A E
AE
Einhäupl
K M
KM
D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D005165:Factor V / Q000235:genetics*; D005260:Female; D005858:Germany; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000097:blood / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011486:Protein C / Q000032:analysis; D017293:Protein S / Q000032:analysis; D012189:Retrospective Studies
D011486:Protein C; D017293:Protein S; D000990:Antithrombin III; D005165:Factor V